2023-03-27 12:07:57 ET
- NRx Pharmaceuticals ( NASDAQ: NRXP ) said Monday the independent Data Safety Monitoring Board has recommended the continuation of a planned patient enrollment for a trial evaluating NRX-101.
- NRX-101 is the company's proposed treatment for severe bipolar depression and subacute suicidal ideation or behavior.
- No safety or futility signals were reported in the first 50 patients enrolled in the trial.
- The company said the trial has been upgraded to a Phase 2b/3 study that may be used for a registrational filing.
- The company expects top-line data from this trial in the fourth quarter of 2023.
- Press Release .
For further details see:
DSMB recommends NRx Pharma to continue trial evaluating its bipolar depression treatment